Publications
Found 15 results
Filters: Author is X. Wei [Clear All Filters]
“Inhibitory effect of microRNA-27b on interleukin 17 (IL-17)-induced monocyte chemoattractant protein-1 (MCP1) expression”, vol. 15, p. -, 2016.
, “Inhibitory effect of microRNA-27b on interleukin 17 (IL-17)-induced monocyte chemoattractant protein-1 (MCP1) expression”, vol. 15, p. -, 2016.
, “RETRACTION of “Immune memory responses to HBV vaccine 13-18 years after primary vaccination” by L. Hou, W. Li, X. Wei, Y. Zhou, Y. Zhuo, H. Wu, B. Shen. Genet. Mol. Res. 14 (3): 8466-8472 (2015)”, vol. 15. p. -, 2016.
, “RETRACTION of “Immune memory responses to HBV vaccine 13-18 years after primary vaccination” by L. Hou, W. Li, X. Wei, Y. Zhou, Y. Zhuo, H. Wu, B. Shen. Genet. Mol. Res. 14 (3): 8466-8472 (2015)”, vol. 15. p. -, 2016.
, , , “Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer”, vol. 14, pp. 16222-16232, 2015.
, “Differential expression of peroxisome proliferator-activated receptor γ, fatty acid synthase, and hormone-sensitive lipase in fat-tailed and thin-tailed sheep breeds”, vol. 14, pp. 15624-15633, 2015.
, “High expression of HIF-2α and its anti-radiotherapy effect in lung cancer stem cells”, vol. 14, pp. 18110-18120, 2015.
, “Immune memory responses to HBV vaccine 13-18 years after primary vaccination”, vol. 14. pp. 8466-8472, 2015.
, “Effects of VEGF suppression by small hairpin RNA interference combined with radiotherapy on the growth of cervical cancer”, vol. 13, pp. 5094-5106, 2014.
, “Genetic diversity and differentiation of the endangered and endemic species Sauvagesia rhodoleuca in China as detected by ISSR analysis”, vol. 13, pp. 8258-8267, 2014.
, “Investigation of mutations in the SRY, SOX9, and DAX1 genes in sex reversal patients from the Sichuan region of China”, vol. 13, pp. 1518-1526, 2014.
, “Association study between Y-chromosome haplogroups and susceptibility to spermatogenic impairment in Han People from southwest China”, vol. 12, pp. 59-66, 2013.
, Ferlin A, Arredi B and Foresta C (2006). Genetic causes of male infertility. Reprod. Toxicol. 22: 133-141.
http://dx.doi.org/10.1016/j.reprotox.2006.04.016
PMid:16806807
Jin L and Su B (2000). Natives or immigrants: modern human origin in east Asia. Nat. Rev. Genet. 1: 126-133.
http://dx.doi.org/10.1038/35038565
PMid:11253652
Karafet TM, Mendez FL, Meilerman MB, Underhill PA, et al. (2008). New binary polymorphisms reshape and increase resolution of the human Y chromosomal haplogroup tree. Genome Res. 18: 830-838.
http://dx.doi.org/10.1101/gr.7172008
PMid:18385274 PMCid:2336805
Kent-First M, Muallem A, Shultz J, Pryor J, et al. (1999). Defining regions of the Y-chromosome responsible for male infertility and identification of a fourth AZF region (AZFd) by Y-chromosome microdeletion detection. Mol. Reprod. Dev. 53: 27-41.
http://dx.doi.org/10.1002/(SICI)1098-2795(199905)53:1<27::AID-MRD4>3.0.CO;2-W
Krausz C and McElreavey K (1999). Y chromosome and male infertility. Front Biosci. 4: E1-E8.
http://dx.doi.org/10.2741/Krausz
PMid:9889182
Krausz C and Degl'Innocenti S (2006). Y chromosome and male infertility: update, 2006. Front Biosci. 11: 3049-3061.
http://dx.doi.org/10.2741/2032
PMid:16720375
Krausz C, Quintana-Murci L, Rajpert-De ME, Jorgensen N, et al. (2001). Identification of a Y chromosome haplogroup associated with reduced sperm counts. Hum. Mol. Genet. 10: 1873-1877.
http://dx.doi.org/10.1093/hmg/10.18.1873
PMid:11555623
Krausz C, Forti G and McElreavey K (2003). The Y chromosome and male fertility and infertility. Int. J. Androl. 26: 70-75.
http://dx.doi.org/10.1046/j.1365-2605.2003.00402.x
PMid:12641824
Kuroki Y, Iwamoto T, Lee J, Yoshiike M, et al. (1999). Spermatogenic ability is different among males in different Y chromosome lineage. J. Hum. Genet. 44: 289-292.
http://dx.doi.org/10.1007/s100380050162
PMid:10496069
Lahn BT, Pearson NM and Jegalian K (2001). The human Y chromosome, in the light of evolution. Nat. Rev. Genet. 2: 207-216.
http://dx.doi.org/10.1038/35056058
PMid:11256072
Maurer B, Gromoll J, Simoni M and Nieschlag E (2001). Prevalence of Y chromosome microdeletions in infertile men who consulted a tertiary care medical centre: the Munster experience. Andrologia 33: 27-33.
http://dx.doi.org/10.1046/j.1439-0272.2001.00406.x
PMid:11167516
Simoni M, Bakker E and Krausz C (2004). EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004. Int. J. Androl. 27: 240-249.
http://dx.doi.org/10.1111/j.1365-2605.2004.00495.x
PMid:15271204
Su B, Xiao J, Underhill P, Deka R, et al. (1999). Y-Chromosome evidence for a northward migration of modern humans into Eastern Asia during the last Ice Age. Am. J. Hum. Genet. 65: 1718-1724.
http://dx.doi.org/10.1086/302680
PMid:10577926 PMCid:1288383
Vogt PH (1998). Human chromosome deletions in Yq11, AZF candidate genes and male infertility: history and update. Mol. Hum. Reprod. 4: 739-744.
http://dx.doi.org/10.1093/molehr/4.8.739
PMid:9733430
Vogt PH, Edelmann A, Kirsch S, Henegariu O, et al. (1996). Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum. Mol. Genet. 5: 933-943.
http://dx.doi.org/10.1093/hmg/5.7.933
PMid:8817327
Wu B, Lu NX, Xia YK, Gu AH, et al. (2007). A frequent Y chromosome b2/b3 subdeletion shows strong association with male infertility in Han-Chinese population. Hum. Reprod. 22: 1107-1113.
http://dx.doi.org/10.1093/humrep/del499
PMid:17204527
Y Chromosome Consortium (2002). A nomenclature system for the tree of human Y-chromosomal binary haplogroups. Genome Res. 12: 339-348.
http://dx.doi.org/10.1101/gr.217602
PMid:11827954 PMCid:155271
Yang Y, Ma M, Li L, Zhang W, et al. (2008). Y chromosome haplogroups may confer susceptibility to partial AZFc deletions and deletion effect on spermatogenesis impairment. Hum. Reprod. 23: 2167-2172.
http://dx.doi.org/10.1093/humrep/den229
PMid:18579508
“Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer”, vol. 9, pp. 1599-1605, 2010.
, Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
http://dx.doi.org/10.2307/2533446
PMid:7786990
Chen WC, Tsai FJ, Wu JY, Wu HC, et al. (2000). Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol. Res. 28: 293-296.
http://dx.doi.org/10.1007/s002400000117
PMid:11127705
Dai S, Mao C, Jiang L, Wang G, et al. (2009). p53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638.
http://dx.doi.org/10.1007/s00439-009-0664-3
PMid:19357867
Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
http://dx.doi.org/10.1136/bmj.315.7109.629
PMid:9310563 PMCid:2127453
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53.
http://dx.doi.org/10.1126/science.1905840
PMid:1905840
Horikawa Y, Nadaoka J, Saito M, Kumazawa T, et al. (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 20: 49-55.
PMid:18575717
Ioannidis JP, Boffetta P, Little J, O'Brien TR, et al. (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol. 37: 120-132.
http://dx.doi.org/10.1093/ije/dym159
PMid:17898028
Jemal A, Siegel R, Ward E, Hao Y, et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96.
http://dx.doi.org/10.3322/CA.2007.0010
PMid:18287387
Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.
http://dx.doi.org/10.1016/S0140-6736(09)60491-8
Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784.
http://dx.doi.org/10.1016/S1470-2045(09)70187-1
Koushik A, Tranah GJ, Ma J, Stampfer MJ, et al. (2006). p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int. J. Cancer 119: 1863-1868.
http://dx.doi.org/10.1002/ijc.22057
PMid:16721787
Lee JM, Shun CT, Wu MT, Chen YY, et al. (2006). The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594: 181-188.
http://dx.doi.org/10.1016/j.mrfmmm.2005.09.003
PMid:16318864
Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
http://dx.doi.org/10.1016/S0092-8674(00)81871-1
Lopez-Beltran A, Escudero AL, Vicioso L, Munoz E, et al. (1996). Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br. J. Cancer 73: 124-127.
http://dx.doi.org/10.1038/bjc.1996.23
PMid:8554974 PMCid:2074275
Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, et al. (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. N. Y. Acad. Sci. 1010: 764-770.
http://dx.doi.org/10.1196/annals.1299.137
PMid:15033824
Maloney KE, Wiener JS and Walther PJ (1994). Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J. Urol. 151: 360-364.
PMid:8283525
Matakidou A, Eisen T and Houlston RS (2003). TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18: 377-385.
http://dx.doi.org/10.1093/mutage/geg008
PMid:12840112
Murgel de Castro Santos LE, Trindade Guilhen AC, Alves de AR, Garcia SL, et al. (2009). The role of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol. Oncol. (in press). DOI: 10.1016/j.urolonc.2009.03.026.
http://dx.doi.org/10.1016/j.urolonc.2009.03.026
Rubben H, Lutzeyer W, Fischer N, Deutz F, et al. (1988). Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139: 283-285.
PMid:3339726
Simoneau M, LaRue H and Fradet Y (1999). Low frequency of human papillomavirus infection in initial papillary bladder tumors. Urol. Res. 27: 180-184.
http://dx.doi.org/10.1007/s002400050107
PMid:10422819
Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 179: 175-183.
http://dx.doi.org/10.1016/S0304-3835(01)00867-9
Sousa H, Santos AM, Pinto D and Medeiros R (2007). Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int. J. Mol. Med. 20: 731-741.
PMid:17912468
Tommiska J, Eerola H, Heinonen M, Salonen L, et al. (2005). Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11: 5098-5103.
http://dx.doi.org/10.1158/1078-0432.CCR-05-0173
PMid:16033823
Toruner GA, Ucar A, Tez M, Cetinkaya M, et al. (2001). p53 codon 72 polymorphism in bladder cancer - no evidence of association with increased risk or invasiveness. Urol. Res. 29: 393-395.
http://dx.doi.org/10.1007/s002400100218
PMid:11828992
Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). p53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486.
http://dx.doi.org/10.1002/ijc.22833
PMid:17546594